Johnson & Johnson company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
THE APEX TIMES
THE APEX TIMES
A recent market analysis highlights an 81.9% gain over three years in Johnson & Johnson stock, while arguing that intrinsic valuation outlines one direction and market multiples suggest another.
THE APEX TIMES
The healthcare giant is reportedly moving to strengthen its position in CAR-T cell therapy through a bid involving Sail Biomedicines, aiming to narrow the gap with Bristol Myers Squibb in treatments for certain blood cancers.
THE APEX TIMES
A recent Yahoo Finance report highlighted CNBC host Jim Cramer’s recurring bullish view of Johnson & Johnson, pointing to what he framed as a stronger balance sheet than the government’s.
THE APEX TIMES
A new Yahoo Finance piece highlights Johnson & Johnson’s dividend appeal and asks whether it suits investors seeking steady cash returns, with no additional operational details provided in the excerpted material for this review.
THE APEX TIMES
The FDA’s expanded approval of Imaavy adds a new treatment indication for warm autoimmune hemolytic anemia, a rare autoimmune blood disorder. Investors will be watching how Johnson & Johnson positions the therapy in a competitive, specialty hematology market.
THE APEX TIMES
A Yahoo Finance investing column argues Johnson & Johnson (JNJ) fits investors’ search for a durable dividend profile in healthcare, but it provides no new company disclosures in the post itself.
THE APEX TIMES
The approval of nipocalimab-aahu as the first treatment shown for warm autoimmune hemolytic anemia (wAIHA) gives Johnson & Johnson a new, narrowly targeted product in a rare autoimmune category.
THE APEX TIMES
The company says the U.S. Food and Drug Administration has approved an autoimmune therapy for a rare blood condition, marking a regulatory milestone for its broader push in specialty immunology.
